Combination cell therapy for advanced melanoma or sarcoma
Part of Cancer, Skin clinical trials.
This trial tests a combination of two medicines: one that trains your immune cells to find cancer (ACTengine IMA203) and another that helps the body recognize the tumor (mRNA-4203). It's for people with advanced melanoma or synovial sarcoma who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have either cutaneous melanoma or synovial sarcoma that has spread or cannot be removed by surgery.
- You need to have a specific gene marker called HLA-A*02:01 (your doctor will test for this).
- You should be able to take care of yourself (ECOG score 0-1) and have a life expectancy of more than 5 months.
- If you have melanoma, you must have tried a PD-1 inhibitor (like immunotherapy) and it didn't work or caused side effects.
- If you have synovial sarcoma, you must have had at least one standard treatment or decided not to have it.
- You cannot have active brain metastases, serious autoimmune disease, or certain heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (MASCT-I) combined with standard chemotherapy (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior chemotherapy or targeted therapy. The goal is to see if the combination works better than chemo alone.
This trial studies an immune-based cancer treatment (IMA203/IMA203CD8) either alone or with nivolumab in people whose solid tumors have come back or will not respond to standard care. It may help by training the immune system to recognize and attack tumor cells that match the trial’s test requirements.
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
This trial tests a new cell therapy called TBI-1301 (Mip-cel) for people with synovial sarcoma that has spread or come back after chemotherapy. It is designed to help your immune system attack the cancer cells that have a specific marker (NY-ESO-1).
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
Hear when a new Cutaneous Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.